Market open
Corcept Therapeutics/$CORT
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Ticker
$CORT
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
352
Website
CORT Metrics
BasicAdvanced
$6.6B
50.26
$1.26
0.46
-
Price and volume
Market cap
$6.6B
Beta
0.46
52-week high
$75.00
52-week low
$20.84
Average daily volume
967K
Financial strength
Current ratio
3.7
Quick ratio
3.509
Long term debt to equity
0.995
Total debt to equity
1.063
Management effectiveness
Return on assets (TTM)
13.00%
Return on equity (TTM)
25.77%
Valuation
Price to earnings (TTM)
50.264
Price to revenue (TTM)
10.377
Price to book
10.39
Price to tangible book (TTM)
10.39
Price to free cash flow (TTM)
45.74
Growth
Revenue change (TTM)
39.67%
Earnings per share change (TTM)
57.97%
3-year revenue growth (CAGR)
21.22%
3-year earnings per share growth (CAGR)
14.94%
What the Analysts think about CORT
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Corcept Therapeutics stock.
CORT Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
CORT Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
CORT News
AllArticlesVideos
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT
Accesswire·2 hours ago
Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript
Seeking Alpha·13 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Stockholders to Connect
Accesswire·2 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Corcept Therapeutics stock?
Corcept Therapeutics (CORT) has a market cap of $6.6B as of February 27, 2025.
What is the P/E ratio for Corcept Therapeutics stock?
The price to earnings (P/E) ratio for Corcept Therapeutics (CORT) stock is 50.26 as of February 27, 2025.
Does Corcept Therapeutics stock pay dividends?
No, Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders as of February 27, 2025.
When is the next Corcept Therapeutics dividend payment date?
Corcept Therapeutics (CORT) stock does not pay dividends to its shareholders.
What is the beta indicator for Corcept Therapeutics?
Corcept Therapeutics (CORT) has a beta rating of 0.46. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.